Seven and Eight Biopharmaceuticals Inc. has signed a clinical research collaboration agreement with Roche Holding AG to explore the combination of BDB-001, an immune modulator targeting Toll-like receptors (TLR) 7 and 8, and atezolizumab, a monoclonal antibody against checkpoint target PD-L1, in treating solid tumors.